Board Recruitment by Occam Global for Clinical Stage Oncology Innovator
Recruitment of Serial CEO to Board for Clinical-Stage Oncology Innovator
In October 2024, Occam Global recruited Jayson Dallas, MD to the Board of Faeth Therapeutics, a clinical-stage precision oncology company whose founding team includes Lew Cantley and Sid Mukherjee, leading experts in the field of cancer metabolism, functional genomics, and tumor metabolism.
Dallas himself is an accomplished commercial executive and serial CEO who brings rich experience across clinical development, medical affairs, commercial strategy and business development. He currently serves as CEO of Rivus Pharmaceuticals, a clinical-stage company targeting cardio metabolic disease.
Dallas joined Rivus from Aimmune Therapeutics, where, as CEO, he oversaw the first-ever approval and launch of a food allergy therapeutic, culminating in a $2.1BN sale to Nestlé Health Science. Prior to Aimmune, Dallas served as Chief Commercial of Ultragenyx Pharmaceuticals. His earlier career entailed several senior positions at Genentech / Roche and Novartis.
About Faeth Therapeutics
Faeth Therapeutics focuses on developing cancer treatments by targeting the unique metabolic dependencies of cancer cells. Using insights from computational biology and machine learning, they analyze the specific metabolic pathways that fuel tumor growth. This approach allows Faeth to design therapies that disrupt multiple key metabolic points within cancer cells, aiming to weaken or eliminate their ability to proliferate.
In addition to their scientific innovation, Faeth offers a patient-centric experience through their app, which helps patients adhere to treatment protocols by customizing their nutritional and metabolic support. Their clinical trials incorporate this targeted metabolic approach, providing patients with personalized guidance to maximize the effectiveness of these therapies. This approach represents a shift in oncology by addressing cancer metabolism as a means to improve treatment outcomes.
Click here to learn more about our life science executive search case studies.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.